A Prospective, Randomized, Double Arm, Controlled Study With Blinded Assessment to Evaluate the Safety and Effectiveness of the Tixel Fractional System in the Treatment of Periorbital Wrinkles in Comparison With Fractional Laser
Phase: NA
Conditions: Wrinkle
Sponsor: Novoxel Ltd.

Synopsis- Clinical Protocol Number: CLN 0460 Rev. 005  
November 24, 2019 
Page 1 of 15 
A PROSPECTIVE, RANDOMIZED, DOUBLE-ARM, CONTROLLED STUDY WITH 
BLINDED ASSESSMENT TO EVALUATE THE SAFETY AND EFFECTIVENESS OF 
THE TIXEL FRACTIONAL SYSTEM IN THE TREATMENT OF PERIORBITAL 
WRINKLES IN COMPARISON WITH FRACTIONAL LASER 
 
Version Date: 
 
November 24, 2019 
 
Investigational Product: 
Tixel Fractional System (Model No. TXLD0002) 
 
 
 
Sponsor: 
 
 
Novoxel Ltd. 
 
 
 
 
43 Hamelaha St. 
 
 
 
 
Poleg Ind. Zone, Netanya,  
Israel 4250573 
Contact: 
 
 
 
 
  
 
 
Ran Iakobovski,  
Director of Clinica  
Ran@novoxel.com 
Raphi Shavit, 
Chairman, Novoxel Ltd. 
Raphi@novoxel.com 
 
 
 

Synopsis- Clinical Protocol Number: CLN 0460 Rev. 005  
November 24, 2019 
Page 2 of 15 
TABLE OF CONTENTS 
 
Introduction: ...........................................................................................................3 
 
Study Objectives: ....................................................................................................5 
 
Primary Outcome Endpoints: .......................................................................5 
 
Safety ...........................................................................................................5 
 
Effectiveness/Performance ..........................................................................5 
 
Secondary Outcome Endpoints ....................................................................5 
 
Inclusion Criteria ....................................................................................................6 
 
Exclusion Criteria ...................................................................................................6 
 
Subject selection: Number of Sites/Investigators ...............................................8 
 
Number of Subjects......................................................................................8 
 
Study Arms ..................................................................................................8 
 
Intended Population .....................................................................................8 
 
Study Design ...........................................................................................................8 
 
Procedure ................................................................................................................9 
 
Study Blinding ........................................................................................................9 
 
Study Flowchart and Follow-Up Assessments ...................................................10 
 
Sample Size Considerations .................................................................................12 
 
Statistical Methods ...............................................................................................12 
 General .......................................................................................................12 
 Primary Performance Endpoint..................................................................12 
 
Safety Assessment ......................................................................13 
 Secondary endpoints ..................................................................................13 
 
Risk Analysis .........................................................................................................14 
 
Expected Possible Side Effects (for both devices) ................................................14 
 
Benefit to subjects ..................................................................................................14 
 
 
 
 

Synopsis- Clinical Protocol Number: CLN 0460 Rev. 005  
November 24, 2019 
Page 3 of 15 
 INTRODUCTION: 
Periorbital Wrinkles are an early manifestation of facial wrinkles1. They are lines or creases that 
form in the skin in the periorbital regions of the face. This is a significantly common multifactorial 
phenomenon, influenced by natural aging, photo aging (including UV exposure), facial 
expressions, skin type, hormonal status, genetic inclination, ethnicity, nutrition and various 
pathological disorders. These intrinsic factors contribute to epidermal thinning, loss of elasticity, 
skin fragility, etc. These are part of the human aging process, which affects the skin in its entirety 
and the facial skin in particular. Additional environmental factors, such as smoking, pollution and 
skin care, also affect periorbital wrinkles2.  
Wrinkles, in general, are reported to appear in people even younger than thirty years of age3. In 
the same manner as any other facial wrinkle, periorbital wrinkles increase gradually and affect 
one’s appearance and facial expression. Such effect also reflects on quality of life, due to impact 
on social interactions, occupational functioning and self-esteem in general4. Therefore, periorbital 
wrinkle reduction treatments are sought by many worldwide.  
Study Title: 
A Prospective, Randomized, Double Arm, Controlled Study with Blinded Assessment To Evaluate 
The Safety And Effectiveness Of The Tixel Fractional System In The Treatment Of Periorbital 
Wrinkles In Comparison With Fractional Laser 
 
Investigational Product: 
Tixel by Novoxel, model No. TXLD0002 
The Tixel system was designed to fulfill a clinical need for fractional treatment for aging skin with 
reduced side effects and safety related complications, associated with current available treatment 
modalities, together with increasing patient comfort. The Tixel employs a thermo-mechanical 
 
1 “A Prospective Split-Face Comparative Study of Periorbital Wrinkle Treatments: Fractional Erbium Doped 
Yttrium Aluminum Garnet Laser Intense Pulsed Light, and Topical 0.1% Tretinoin Cream”, 
So Eun Park, Sang Seok Kim, Chul Woo Kim, Young Her, Department of Dermatology, Kangdong Sacred Heart 
Hospital, Hallym University College of Medicine, Seoul, 
1Department of Dermatology, Kangwon National University Hospital, Kangwon National University School of 
Medicine, Chuncheon, Korea 
2 https://www.mayoclinic.org/diseases-conditions/wrinkles/symptoms-causes/syc-20354927 
3 “Wrinkles”, Juan Manríquez, Daniela Majerson Grinberg, and Claudia Nicklas Diaz, Clinical Evidence 
2008;12:1711 
4 Gupta MA, Gupta AK. Photodamaged skin and quality of life: reasons for therapy. 
J Dermatol Treat 1996;7:261–264. 

Synopsis- Clinical Protocol Number: CLN 0460 Rev. 005  
November 24, 2019 
Page 4 of 15 
technology that has been designed to provide a comparable clinical effect as a pulsed laser, which 
can be used as a treatment modality for a variety of applications, including fractional treatment of 
human skin. The Tixel technology is based on the supply of contact-transferred heat from a high 
temperature (385°- 400°C) metal element (called a “tip”) consisting of an array of miniature 
pyramids. The tip creates a thermal effect in the tissue (usually 200-300 microns deep) in the tissue 
within 5 – 16 milliseconds, thus mimicking the pulsed laser action. The tip thermally generates a 
matrix of coagulation sites (or “micropores”) on the skin. Dermal heating and coagulative effect 
that occur during the treatment session provide for dermal remodeling and collagen restructuring 
that promote wrinkle reduction and general wrinkle appearance improvement. 
 
Protocol Number: 
CLN 0460  
 
Study Design: 
Prospective, single-blinded, randomized, controlled study 
 
Number of Study Sites: 
2 
 
Study Population: 
Male and female subjects between 40-70 years of age (inclusive) diagnosed with clinically evident 
periorbital wrinkles 
 
Study Treatment: 
Subjects will be treated with the Tixel for periorbital wrinkles every 4-6 weeks for a series of 3 to 
5 treatment sessions followed by 3 follow up sessions (see flowchart for full schedule details and 
options). The number of treatments may vary from subject to subject and shall be determined by 
the investigators’ assessment of the subjects’ improvement. 
The minimal estimation for study duration per subject is 27 weeks, and the maximal estimation is 
47 weeks (please see study flowchart for further details). 
 
 
 

Synopsis- Clinical Protocol Number: CLN 0460 Rev. 005  
November 24, 2019 
Page 5 of 15 
Comparator Treatment: 
The ResurFX Non-Ablative Laser with the M22 device by Lumenis (1565 nm) for treatment of 
periorbital wrinkles 
 
 STUDY OBJECTIVES: 
 
To demonstrate the safety and performance of the Tixel fractional system for treatment of 
periorbital wrinkles in comparison to the selected market-cleared comparator.  
 Primary Outcome Endpoints:   
Each subject shall be assessed based on FWCS. Each subject shall contribute two separate data 
time points to the study.  
 Safety 
Physical and dermatological examinations, erythema, and adverse events (such as PIH, burns, etc.) 
monitoring will be performed and assessed at every visit (including follow up visits). 
 Effectiveness/Performance 
Effectiveness/Performance shall be assessed and quantified by 3 blinded assessors. 
The following assessment method will be applied by the blinded assessors (by images only):  
• 
FWCS - Fitzpatrick Wrinkle Classification System  
 Secondary Outcome Endpoints 
The following criteria will be assessed as secondary outcome endpoints: 
• 
Secondary Effectiveness/Performance shall be assessed and quantified by a handling 
physician (one of the team’s investigators of the study). 
The following assessment methods will be applied (frontal clinical assessment or by images): 
• 
FWCS - Fitzpatrick Wrinkle Classification System 
• 
GAIS - Global Aesthetic Improvement Scale Assessment  
• 
WAS - 5-point Wrinkle Assessment Scale 
• 
Subject Experience  
• 
Pain Level VAS Scale  
• 
Subject Subjective Downtime Assessment  

Synopsis- Clinical Protocol Number: CLN 0460 Rev. 005  
November 24, 2019 
Page 6 of 15 
• 
Subject redness, edema and crust assessment (time for resolution) 
• 
End-User Experience Assessment  
Clinic Visits Baseline, 4wk, 8wk, (optional 12wk and 16wk), 20wk, 28wk, 42wk 
 
 INCLUSION CRITERIA 
 
1. 
Male or female 40-70 years old diagnosed with clinically evident fine (mild) to 
moderate depth periorbital wrinkling 
2. 
Willingness and ability to comply with all required study activities and protocol 
requirements. 
3. 
The subject is able to provide written informed consent and perform the study’s 
activities according to HIPAA guidelines and/or Israeli law, depending on each 
specific study site.  
 EXCLUSION CRITERIA 
 
1. 
The subject may not undergo treatment by the Tixel or comparator device according 
to the device’s contra-indications for use, as defined in the User Manual and in the 
Instructions for Use and by any other labeling of the device.  
2. 
Female subjects who are pregnant, or planning to become pregnant, or have given 
birth less than 3 months ago or are lactating.  
3. 
Subjects with significant exposure to critical amounts of ultraviolet light (Sun tan).  
4. 
Subjects who have had the following treatments: 
a. a prior cosmetic procedure to improve facial rhytides (i.e., rhytidectomy, 
periorbital 
or 
eyelid/eyebrow 
surgery, 
brow 
lift, 
CO2/Erbium/similar 
laser/fractional resurfacing, radiofrequency treatment) within 12 months  
b. prior facial treatments with laser, surgical, chemical or light based facial 
treatments within the previous 6 months, such as for botulinum toxin injections, 
retinoid, microdermabrasion or prescription level glycolic acid treatments 
c. Injectable filler in area to be treated within 9 months of investigation. 
d. permanent facial implant  
5. 
Any subject who have visible scars that may affect evaluation of response and/or 
quality of photography. 

Synopsis- Clinical Protocol Number: CLN 0460 Rev. 005  
November 24, 2019 
Page 7 of 15 
6. 
Subjects with any type of active cut, wound, inflammation, lesion (benign, 
premalignant or malignant) or active bacterial, viral, fungal, or herpetic infection on 
the skin on the designated treatment sites or in close proximity to it. 
7. 
Existing or history of the following (when discussing skin conditions, refers only to 
the periorbital sites): 
a. skin malignancy, or any diagnosis of suspected malignancy 
b. Collagen or vascular or bleeding disease 
c. Immunosuppression or autoimmune disease 
d. Erythema with or without blistering 
e. History of post inflammatory hyperpigmentation. 
f. Active Acne Vulgaris, HSV-1, or any existing skin condition/disease that in the 
investigator’s opinion would interfere with the evaluation of the safety of the study 
treatment. 
g. Any skin pathology which can induce bullous lesions, urticaria, or demonstrate a 
Koebner phenomenon (psoriasis, lichen planus, etc.). 
h. Any disease that inhibits pain sensation 
i. History of keloid formation, or hypertrophic scarring 
j. Conditions affecting healing rate (i.e. diabetes mellitus I or II, vascular condition, 
etc.) 
k. neuromuscular disorders 
8. 
Subjects who have used, within 30 days, any medication that can cause dermal 
hypersensitivity or affect skin characteristics (i.e. topically applied Retinoids, 
Hydroquinone, Chemical peel of any strength: glycolic acid, lactic acid, salicylic acid) 
9. 
Subjects who have used, systemic treatment which may induce dyspigmentation, such 
as amiodarone, clofazinmine, minocycline or chloroquine. 
10. Subjects currently taking or have taken an oral retinoid in the past six months (risk of 
scarring with therapy); Subjects currently taking long-term oral steroid treatment 
(causing fragility of the skin, risk of hematoma and bullae formation); Subjects taking 
Isotretinoin (Accutane or Roaccutan) within past 12 months. 
11. Concurrent therapy that, in the principal investigator's opinion, would interfere with 
the evaluation of the safety or efficacy of the study treatment. 
12. Subjects who anticipate the need for surgery or overnight hospitalization during the 
study. 

Synopsis- Clinical Protocol Number: CLN 0460 Rev. 005  
November 24, 2019 
Page 8 of 15 
13. Enrollment in any active study involving the use of investigational devices or drugs. 
14. Any other cause per the principal investigator’s discretion. 
 SUBJECT SELECTION: NUMBER OF SITES/INVESTIGATORS 
There will be two investigational sites participating in this study, including one site in the U.S. and 
one in Israel. 
 Number of Subjects 
A total of 82 subjects will be recruited to the study. They will be randomly split to two separate 
arms (41/arm) in each site, and undergo periorbital fractional treatments. 
 Study Arms 
Subjects will be randomly assigned to one of the following groups: 
• Group I:  Tixel 
• Group II: The ResurFX Non-Ablative Laser with the M22 device by Lumenis 
(1565 nm)  
 Intended Population  
Male or female 40-70-year-old diagnosed with clinically evident periorbital wrinkling.   
At least one of each Fitzpatrick skin type I to IV must be included in the study.  In addition to this 
definition, all Fitzpatrick skin types (I-VI) may participate in the study. For clarity’s sake, it is 
emphasized that not every site must have all skin types I-IV, but the entirety of the study’s 
population.  
 STUDY DESIGN 
The study is designed to explore the safety and effectiveness of the Tixel, a novel fractional device, 
in treatment of periorbital wrinkles in comparison to a currently market-available product, which 
applies fractional treatment. The study is designated to compare between the effect of a currently 
available fractional pulsed laser modality (the “comparator”), market-cleared in the US for the said 
purpose, and the Tixel.  

Synopsis- Clinical Protocol Number: CLN 0460 Rev. 005  
November 24, 2019 
Page 9 of 15 
This is an interventional, double-arm, controlled, randomized, prospective, multi-center (US, 
Israel), clinical study with single-blinded evaluation. The Tixel treatment results will be compared 
to a laser modality indicated for the same purpose. 
 PROCEDURE 
Prior to beginning treatment, the subject will be given post-care instructions regarding skin care 
after treatment. Once the post-care instructions are reviewed with the subject, treatment may 
commence.   
The subject’s face should be gently cleansed with water and soap (hypoallergenic allowed) or any 
other cleansing materials customary for use prior to fractional treatment sessions, in order to 
remove any excess material from the skin such as natural oil, mascara clumps, etc.  No materials 
with active ingredients shall be used in order to avoid interference with the study’s objectives. All 
materials applied shall be documented in the CRF including method of application.  
The study team member performing the cleansing shall be responsible for closely examining the 
subject’s facial skin to ensure it is clean and dry. In case other cleaning procedures are customary 
in the study sites, they are acceptable as long as supervised and approved by one of the study’s 
investigators, and as long as they are performed uniformly on the entire periorbital site and its 
immediate peripherals.  
 STUDY BLINDING 
This study is single blinded with limited access to the randomization code. Every effort will be 
made to retain the integrity of the blinding.  Subjects will be randomized post-screening. 
The treatment each subject shall receive will not be disclosed to any of the investigators until 
subject screening and enrollment is complete. The same shall apply regarding study site personnel, 
subjects, monitors, or the Sponsor staff except as required for the purposes of conducting this 
study. 
The blinded evaluators shall not be exposed to the information, as well, in order to keep their 
assessment objective.  

Synopsis- Clinical Protocol Number: CLN 0460 Rev. 005  
November 24, 2019 
Page 10 of 15 
 
 
 STUDY FLOWCHART AND FOLLOW-UP ASSESSMENTS 
Procedure 
Visit 1 
 
Treatment 1c 
Visit 2 
 
Treatment 2 
 
Visit 3 
 
Treatment 3 
Visit 4 
 
Treatment 4 
Optional 
Visit 5 
 
Treatment 5 
Optional 
Visit 6 
1 month 
Follow-up  
1 
Visit 7 
3 months 
Follow-up  
2 
Visit 8 
6 months 
Follow-up  
3 
T0 
f 
T0 + 4w 
(± 5d) ± ∆ef 
T0 + 8w 
(± 5d)± ∆ 
T0 + 12w 
(± 5d) ± ∆e 
T0 + 16w 
(± 5d) ± ∆e 
T0 + 20w 
(± 8d) ± ∆ e 
T0 + 28w 
(± 8d) ± ∆ e 
T0 + 42w 
(± 8d) ± ∆ e 
Max duration 
- 
4w+5d 
8w+10d 
12w+15d 
16w+20d 
20w+25d 
28w+33d 
40w+41d ~ 47w 
Min duration 
- 
4w-5d 
8w-10d 
- 
- 
12w-15d 
20w-23d 
32w-29d ~28w 
Subject Screening, Enrolment Procedure 
& Informed Consentg, Post treatment care 
instructions 
X 
 
 
 
 
 
 
 
Facial dermatological skin examination   
X 
X 
X 
X 
X 
X 
X 
X 
Inclusion/ Exclusion criteria 
X 
 
 
 
 
 
 
 
Medical/Surgical history 
X 
 
 
 
 
 
 
 
Demographics 
X 
 
 
 
 
 
 
 
Limited Physical examinationa 
X 
 
 
 
 
 
 
 
Concomitant Therapy/Medication 
Xb 
X 
X 
X 
X 
X 
X 
X 
Verbal Inquiry regarding pregnancy 
X 
X 
X 
X 
X 
X 
X 
X 
Photography of Treatment Area(s) – prior 
to treatment 
X (baseline( 
X 
X 
X 
X 
X 
X 
X 
Photography of Treatment Area(s) – After 
treatment 
 
 
X 
 
 
 
 
 
Investigational/Comparator 
Device  
Treatment 
X 
X 
X 
X 
X 
 
 
 
Subject 
experience 
and 
satisfaction 
questionnaire  
X 
 
X* 
X* 
X * 
X* 
 
X 

Synopsis- Clinical Protocol Number: CLN 0460 Rev. 005  
November 24, 2019 
Page 11 of 15 
a. 
A limited physical examination will be performed at Screening to support the eligibility determination. System review will include general appearance, and a routine 
physical examination, according to the standard of care and as customary for fractional treatments.  
b. At Screening, the review of concomitant medications should include those taken within the past year. 
c. 
All assessments on treatment days are to be performed prior to treatment; the assessments performed prior to Treatment 1 will be designated as Baseline. 
d. Treatment sessions 4 & 5 are optional for both treatment options, based on the investigator's assessment of the subject's response. 
e. 
The sign ∆ signifies the possibility of the change of the study’s duration. Any delay of this sort will be documented and explained in writing. 
f. 
Blinded assessment performed in addition to physician assessment. Shall be performed at the end of the subject's activities. 
g. First visit may be split into two separate visits: part I: screening, enrollment and informed consent, and part II: rest of visit content (see in  שגיאה! מקור ההפניה לא
.נמצא) 
*  The * symbol is designated to show that filling out the Subject experience and satisfaction questionnaire is optional and should only be performed in one of the visits 
marked by the symbol. This is because it may be determined in a specific treatment visit (no. 4 or no. 5) that no more treatments are required. Therefore, the questionnaire 
Procedure 
Visit 1 
 
Treatment 1c 
Visit 2 
 
Treatment 2 
 
Visit 3 
 
Treatment 3 
Visit 4 
 
Treatment 4 
Optional 
Visit 5 
 
Treatment 5 
Optional 
Visit 6 
1 month 
Follow-up  
1 
Visit 7 
3 months 
Follow-up  
2 
Visit 8 
6 months 
Follow-up  
3 
GAIS Assessment 
 
X 
X 
X 
X 
X 
X 
X 
FWCS Assessment  
Xf 
X 
X 
X 
X 
X 
X 
Xf 
WAS Assessment  
Xf 
X 
X 
X 
X 
X 
X 
Xf 
Subject VAS Pain assessment 
X 
X 
X 
X 
X 
 
 
 
Subject 
Assessment 
Questionnaire  
(regarding downtime, skin erythema, 
redness and scabs) 
 
X 
X 
X 
X 
X 
 
 
Adverse Events 
X 
X 
X 
X 
X 
X 
X 
X 
Subject Compliance 
X 
X 
X 
X 
X 
X 
X 
X 
Post Treatment Care Instructions 
X 
X 
X 
X 
X 
 
 
 

Synopsis- Clinical Protocol Number: CLN 0460 Rev. 005  
November 24, 2019 
Page 12 of 15 
should be filled out in the last treatment visit or in a following visit. For convenience purposes, it is also allowed to have the questionnaire filled out by the subject in the 
first follow-up visit.

Synopsis- Clinical Protocol Number: CLN 0460 Rev. 005  
November 24, 2019 
Page 13 of 15 
 
SAMPLE SIZE CONSIDERATIONS 
The rationale for sample size calculation was based on difference between treatments arms in the 
improvement post treatment in FWCS scores.   
Improvement=𝐹𝑊𝐶𝑆6 𝑚𝑜𝑛𝑡ℎ𝑠−𝐹𝑊𝐶𝑆𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒 
NIM=𝐼𝑚𝑝𝑟𝑜𝑣𝑒𝑚𝑒𝑛𝑡𝑇𝑖𝑥𝑒𝑙−𝐼𝑚𝑟𝑜𝑣𝑒𝑚𝑒𝑛𝑡𝐿𝑎𝑠𝑒𝑟≥−0.5 
The assumption that Tixel is non inferior as compared to Laser in the effectiveness as evaluated by FWCS 
6 months after first treatment. 
FWCS ranges from fine to deep wrinkles in a 1 to 9 scale. 
Previous studies demonstrated that the standard deviation of the change in FWCS post 6 months is 0.75.  
Assuming that the non-inferiority margin is ≥−0.5, and the SD=0.8 a sample size of 32 completers 
per group will enable to conclude that Tixel in non inferior to ResuFx with 95% confidence and with 
80% power. 
Taking into account a dropout rate of 20% a total of 40 cases per group should be recruited.To allow for 
the possibility of a higher dropout rate a total of 41 cases per group will be recruited. 
 
STATISTICAL METHODS 
11.1 General 
All measured variables and derived parameters will be listed individually and, if appropriate, tabulated 
by descriptive statistics.  
For categorical variables summary tables will be provided giving counts and percentages. 
For continuous variables summary tables will be provided giving count, arithmetic mean, standard 
deviation, median, 25th and 75th percentile, minimum and maximum of variables by device.  
All tests will be two-tailed, and a p-value of 5% or less will be considered statistically significant. 
The data will be analyzed using the SPSS version 925.0. 
11.2 Primary Performance Endpoint 
FWCS scores will be summarized per subject and time point. Changes from baseline to the last follow-
up visit will be summarized as well. For analyzing the changes over time within each arm, the Repeated 

Synopsis- Clinical Protocol Number: CLN 0460 Rev. 005  
November 24, 2019 
Page 14 of 15 
measures or Friedman paired test followed by Dunn’s post hoc test (as appropriate based on Shapiro and 
Wilk test for normality) will be applied. For comparison between devices  two-sample T-test or Non-
parametric, Mann-Whitney Rank sum test (as is appropriate) will be applied. 
In addition, in order to keep the study's power, data of the two sites will be pooled together and an 
Analysis of Covariance (ANCOVA) model will be applied for analyzing the primary endpoint, with 
adjustment to suspected confounders (baseline measure and site). 
11.2.1 Safety Assessment 
Frequency and incidence of physical and dermatological examinations will be summarized. 
Adverse events will be reported in tabulated format based on all ITT (intent to treat data set).   
11.3 Secondary endpoints 
All parameters below will be summarized at baseline condition and all post-baseline conditions. The 
change from baseline to the last follow-up will be analyzed using Wilcoxon paired test. 
The following secondary endpoints will be summarized in appropriate tables by device and visit: 
11.3.1.1 FWCS - Fitzpatrick Wrinkle Classification System 
11.3.1.2 GAIS - Global Aesthetic Improvement Scale Assessment  
11.3.1.3 WAS - 5-point Wrinkle Assessment Scale 
11.3.1.4 Subject Experience  
11.3.1.5 Pain Level VAS Scale  
11.3.1.6 Subject Subjective Downtime Assessment 
11.3.1.7 Subject Response Questionnaire (redness, edema and crust - time to resolve)  
11.3.1.8 End-User Experience Assessment  
11.3.1.9 Repeated measures or Friedman’s test (as is appropriate) will be applied for analyzing the changes 
within side (device) and .The two-sample T-test or Non-parametric Mann-Whitney Rank test (as is 
appropriate) will be applied for comparative analysis of the changes between the devices. 

Synopsis- Clinical Protocol Number: CLN 0460 Rev. 005  
November 24, 2019 
Page 15 of 15 
12 RISK ANALYSIS 
By enrollment to the study and following its procedures, the subjects shall face the risk of all side effects 
of both the Tixel and the comparator device, listed in the devices’ labeling.  The risks are, in general, the 
known risks of non-ablative fractional lasers (for comparator treatments), and similar risks (for Tixel 
treatments), excluding radiation and fume hazards.  
Due to randomization, the subject will be notified of worst case, meaning the known risks of the non-
ablative fractional laser. 
Potential side effects exist. See following section.  
13 EXPECTED POSSIBLE SIDE EFFECTS (FOR BOTH DEVICES) 
In the same manner as all fractional skin treatment devices, there is some risk of: Temporary swelling; 
Skin redness; Pain and/or burning sensation; Forming of large scabs or scabs lasting more than 15 days; 
Significant/thick skin peeling and/or peeling; Post Inflammatory Hyperpigmentation (PIH); Hypo-
pigmentation; Sensitivity to sun exposure; Local burns; Scars; Local bacterial infection.  
. 
There is also the risk of loss of confidentiality.  However, safeguards will be implemented to reduce this 
risk, including coding of data and images. 
14 BENEFIT TO SUBJECTS 
By enrollment to the study and following its procedures, the subjects shall have the following benefits 
from the study: 
• Dermatological examination by an experienced physician. 
• Periorbital Wrinkles assessment and treatment by fractional skin resurfacing by an expert 
physician. 
• The chance to contribute to the scientific exploration and to the market clearance of a fume-free, 
radiation free, eye-safe non-ablative fractional device.